China’s biotech rise is fueled by its 'first to file' patent system. Companies feed newly published patents into computers to design trivially different but functionally identical molecules, effectively creating a 'shadow generic industry' that undermines IP.

Beyond innovation or speed, the key structural advantage for the U.S. biotech ecosystem is its deep, unparalleled capital market. This financial moat makes it difficult for Chinese firms to access the scale of funding needed to truly dominate the global landscape.

To capitalize on promising Chinese biotech assets while mitigating risks in IP and manufacturing (CMC), investors are creating new US-based companies ("NewCos"). This structure allows an experienced US leadership team and board to guide the asset's development to meet global regulatory standards.

When a major US company like Bristol Myers Squibb invests in a Chinese biotech, it's not just a sign of global competition. It signifies a deliberate withdrawal of capital from the American biotech ecosystem. This migration of innovation and funding is a clear warning that the US is losing its strategic advantage.

With Chinese biotechs developing therapies at unprecedented speed, a Western startup's primary defense is carefully managing its intellectual property. This requires being highly strategic about when to file patents, what to publish, and what to share publicly, as any information can be rapidly replicated by fast-moving global competitors.

The old narrative of China's IP theft is outdated. Today, China's competitive advantage in sectors like biotech comes from its massive scale, significant resources, and collective lack of profit sensitivity. This combination allows it to dominate industries and destroy profitability for other global players, as previously seen in solar and EVs.

Over the last four years, China has become a life sciences powerhouse, capturing 50% of U.S. pharma's outsourced research spend. This rapid shift, combined with their patent output, threatens America's leadership in biotech and drug development.

To navigate tensions that hinder direct acquisitions by US firms, Chinese biotechs are licensing molecules to new, separate companies established by US investors. This non-Chinese entity can then be more easily acquired by a US pharma company, sidestepping political friction.

According to investor Joe Edelman, China's main strength is developing new molecules. This means US and European firms will increasingly in-license drugs from China, creating fierce competition for the small US biotechs that traditionally filled this pipeline role for larger pharmaceutical companies.